Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Xinglei Chai"'
Autor:
Kimberly Guinan, Karine Mathurin, Yunghan Au, Andre C. Schuh, Cat N. Bui, Xinglei Chai, Jean Lachaine
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7524-7536 (2022)
Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC. The purpose of this study was to evaluate, fro
Externí odkaz:
https://doaj.org/article/bf0b243931014d68b508d082835e8efb
Autor:
Keith W. Pratz, Xinglei Chai, Jipan Xie, Lei Yin, Xiaoyu Nie, Melissa Montez, Erica Iantuono, Lisa Downs, Esprit Ma
Publikováno v:
PharmacoEconomics. 40:777-790
Using individual patient-level data from the phase 3 VIALE-A trial, this study assessed the cost-effectiveness of venetoclax in combination with azacitidine compared with azacitidine monotherapy for patients newly diagnosed with acute myeloid leukemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e46c588221d14d36526ef5a79bb97b7
https://doi.org/10.1007/s40273-022-01145-7
https://doi.org/10.1007/s40273-022-01145-7
Autor:
Richard T. Maziarz, Jie Zhang, Hongbo Yang, Xinglei Chai, Chengbo Yuan, Elisabeth Schwarz, Mihael Jakovac, Marcela Martinez-Prieto, Abhijit Agarwal, Evgeny Degtyarev, Constantine Tam, Gilles Salles
Publikováno v:
Blood Advances. 6:2536-2547
No head-to-head trials have compared the efficacy of tisagenlecleucel vs historical treatments for adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study indirectly compared the overall survival (OS) and overall resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e33567bd5c6af638763c6753150e911
https://doi.org/10.1182/bloodadvances.2021006280
https://doi.org/10.1182/bloodadvances.2021006280
Autor:
Jenny Zhou, Xinglei Chai, Rajeev Ayyagari, Eric Q. Wu, Steve L Hass, Sarah M Donelson, Shengsheng Yu, Stephen A Tilles, Jun Liu, Dan Robison, Alex Smith
Publikováno v:
Advances in Therapy
Introduction The phase 3 trial PALISADE, comparing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) oral immunotherapy versus placebo in peanut-allergic children, reported that a significantly higher percentage of PTAH-treated participants toler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79210f0b7c1decaa240b9a0febb5f8a1
http://europepmc.org/articles/PMC8264172
http://europepmc.org/articles/PMC8264172
Autor:
Michelle Choi, Jinlin Song, Cat N Bui, Esprit Ma, Xinglei Chai, Lei Yin, Keith A Betts, Tatyana Kapustyan, Melissa Montez, Thomas William LeBlanc
Publikováno v:
Journal of managed carespecialty pharmacy. 28(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::840b455f91b43131272baecdcff63c8d
https://pubmed.ncbi.nlm.nih.gov/35708343
https://pubmed.ncbi.nlm.nih.gov/35708343
Autor:
Michael Dickinson, Joaquin Martinez-Lopez, Etienne Jousseaume, Carla Anjos, Hongbo Yang, Xinglei Chai, Cheryl Xiang, Travis Wang, Roberto Ramos, Chiara Lobetti-Bodoni, Stephen J. Schuster, Nathan H. Fowler
Publikováno v:
Transplantation and Cellular Therapy. 28:S65-S66
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::232dafc26d95e5ceedd12f8bc22bf692
https://doi.org/10.1016/s2666-6367(22)00238-x
https://doi.org/10.1016/s2666-6367(22)00238-x
Autor:
Shiho Wakase, Eric Q. Wu, Takanori Teshima, Yoko Watanabe, Jie Zhang, Qiufei Ma, Hongbo Yang, Ataru Igarashi, Xinglei Chai, Yanwen Xie, Cynthia Z. Qi
Publikováno v:
Transplantation and cellular therapy. 27(3)
Until recently, treatment options were relatively limited for children and young adults with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Tisagenlecleucel is a chimeric antigen receptor T cell (CAR-T) immunotherapy with promising
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb578f10d0729e7779a4f1b62851974d
https://pubmed.ncbi.nlm.nih.gov/33781519
https://pubmed.ncbi.nlm.nih.gov/33781519
Autor:
Timothy R. Rebbeck, Jinbo Chen, Tsun Leung Chan, Edmond S. K. Ma, Ava Kwong, Vivian Y. Shin, Xinglei Chai, Lingjiao Zhang, Alan Zhang
Publikováno v:
Oncotarget
// LingJiao Zhang 1, * , Vivian Y. Shin 2, * , Xinglei Chai 1 , Alan Zhang 3 , Tsun L. Chan 4, 5 , Edmond S. Ma 4, 5 , Timothy R. Rebbeck 6 , Jinbo Chen 1 and Ava Kwong 2, 5, 7 1 Department of Biostatistics, Epidemiology, and Informatics, University
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df7fe07bb015457f03ba6539619bc559
http://europepmc.org/articles/PMC5982775
http://europepmc.org/articles/PMC5982775
Autor:
Qiufei Ma, Xinglei Chai, Taizo Fujita, Cynthia Z. Qi, Eric Q. Wu, Shiho Wakase, Jie Zhang, Takanori Teshima, Qing Liu, Hongbo Yang, Ataru Igarashi
Publikováno v:
Transplantation and Cellular Therapy. 27:506.e1-506.e10
There are limited treatment options and substantial unmet needs for adult patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) in Japan. In 2019, tisagenlecleucel, a CD19-directed chimeric antigen receptor T cell therapy, wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c8791c71811d62d6c64cea31f1c59d3
https://doi.org/10.1016/j.jtct.2021.03.005
https://doi.org/10.1016/j.jtct.2021.03.005
Publikováno v:
Blood. 134:4723-4723
INTRODUCTION: Acute lymphoblastic leukemia (ALL) is a hematological malignancy that primarily affects children, adolescents, and young adults. Patients with refractory disease or in second or later relapse have a poor prognosis and are less likely to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65caed1a3b6a23ef8079abd7d5ef17c
https://doi.org/10.1182/blood-2019-129215
https://doi.org/10.1182/blood-2019-129215